Glooko Raises $30 Million Financing

Funding will help maker of remote monitoring platform for diabetes patients accelerate its market growth.

glooko logoDiabetes data and remote patient management company Glooko has raised a $30 million Series D round funding.

The financing was led by Health Catalyst Capital along with participation from existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet and Mayo Clinic.

“As a result of Glooko’s innovations, the company has experienced rapid market adoption growing its global ecosystem to more than 7,500 clinics and has entered into partnerships with many of the world’s largest diabetes medical device companies and pharmaceutical companies as well as top healthcare systems,” said Charles Boorady, founder and managing partner of Health Catalyst Capital.

The new funds will expedite Glooko’s execution of its commercial strategy, including increasing adoption of Glooko’s remote patient monitoring platform, widening commercialization of products in clinical research and expanding into additional therapy areas.

“This is an unprecedented time in healthcare and technology,” said Russ Johannesson, CEO of Glooko. “The demand for our platform demonstrates this sea-change. Glooko has experienced considerable growth, and this funding allows us to build on our strong momentum in providing the advanced technologies we’re known for.”

HME Business Podcast

Latest Podcasts